UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in charter)
(State or other jurisdiction | (Commission | (IRS Employer | ||
of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) | ||||
(The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company
If
an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
On August 23, 2021, Jupiter Wellness, Inc. (the “Company”) issued a press release announcing that it has requested a pre-Investigational New Drug meeting with the U.S. Food and Drug Administration in support of its JW-100 drug development program the treatment of patients with mild to moderate eczema.
A copy of the press release is attached as Exhibit 99.1 to this report and incorporated into this Item 7.01 by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibits
Exhibit No. | Description | |
99.1 | Press Release dated August 23, 2021 | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 23, 2021
JUPITER WELLNESS, INC. | ||
By: | /s/ Brian John | |
Brian John | ||
Chief Executive Officer |
Exhibit 99.1
Jupiter Wellness Submitted a Pre-IND Meeting Request with
the US FDA for its Proposed Clinical Program of JW-100 as a
Treatment for Mild to Moderate Eczema
Following receipt of a Pre-Assignment number from the FDA Jupiter Wellness requests Pre-IND meeting
JUPITER, FL / ACCESSWIRE / August 23, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a developer of enhanced skin care therapeutics and treatments focused on the endocannabinoid system today announced it has submitted a pre-IND (Investigational New Drug) meeting request with the U.S. Food and Drug Administration (FDA) in support of its JW-100 drug development program the treatment of patients with mild to moderate Eczema .
The benefits of holding a pre-IND meeting are to receive early FDA feedback on proposed preclinical and clinical study plans confirming strategy for IND submission.The FDA’s statistics show that this can significantly reduce overall development times which impacts time to market.
The Global Eczema (atopical dermatitis) treatment market is valued at $10 billion and expected to grow at a CAGR of 13% from 2020-2025. 31.6 million Americans or roughly 10% of the population suffer from Eczema. 86% are not satisfied with their current treatment.
Through the Company’s research and development program, it has shown that in a double-blinded, placebo controlled clinical trial, JW-100 significantly reduced ISGA scores in 50% of adult patients suffering from eczema and JW-100 cleared or reduced eczema following 2 weeks of use.
About Jupiter Wellness
Jupiter Wellness, Inc. (NASDAQ:JUPW) is a leading developer of skin care therapeutics and treatments. The Company’s product pipeline of enhanced skin care therapeutics focuses on the endocannabinoid system to address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates revenue from a growing line of proprietary over-the-counter skincare products including its CaniSun™ sunscreen and other wellness brands sold through www.cbdcaring.com.
For additional information, please visit www.JupiterWellness.com. The Company’s public filings can be found at www.Sec.gov.
Safe Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”) contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and assumptions made by the company’s management. These statements can be identified by the fact that they do not relate strictly to historic or current facts. When used in this presentation the words “estimate,” “expect,” intend,” believe,” plan,” “anticipate,” “projected” and other words or the negative of these terms and similar expressions as they relate to the company or the company’s management identify forward-looking statements. Such statements reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the company’s industry, its operations and results of operations and any businesses that may be acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor
& Public Relations Contact Info
Phone: 561-244-7100
Email: info@JupiterWellness.com
*$,W])^)HK7VA;Z01&%;%3LEXRE??O=V7+
M#/FI=]YV2 K#+7\$XRG-VW-_U E'Z<<>;I__HH!KE(ILYC7\OV9T[P ']]OZ
M^J\1L/6/#0"O-&P/M]+C!T"-T.$!T-P[X[/GI0_,SK&:1#P$)>>\"\ZL-D>0
MFQLCT_S8;RZ-D7%^N>0,%@KV ?@]E-+L;NQ)8G$0?/TW4$L#!!0 ( !9D
M%U.?H!OPL0( .(, - >&PO -8?20$3;8T.P6BP^0"X99K>]
M9!:G
N9X1LW-N8
M(LW+IC1%>\>"Y3>$N0J/;F S2F4]EQ&.I%O_>"DQ#VVUG!1+3.]N2Z1%0IXS
M&-!#F.*6X0BM53BF$;I:&-'5Z-@_SM!JNB<&=V* [K- 03-5N"L+&U7PJO-N
M3[8Z*U&!LJ@ZI"4PW#Y?7T4;VMLB..P+97Z'3.G]P6;H68=6_LE(-=I&DF
M""%SX9=K\"/ F_I@&(D 6&5(20:0(D^*,UL"M =T^+\K5T_*-@V-%.E@U.5/@0?F>+$I.
MX&2JF>"EZ;>:-=\U-&];C>=4HG.+.ZNF9@)Z*!>/)U*I+QE^\>@1\52+PLAH
M%M81Z1/%8=H3#\G ND'L;;0%Q").[5>+OZP-KP.6"5_G\+F>IP3/E^5&Z3I?
M>K*D^]HJG*9Q>" $R5UI>X[TSFX7YCV<3TPP2VL=TWC199>:M>->9E"NII
MSXSPGH89RLF)1#@EQ1;R[M9-(+9&<=W__CLM2ZD]F(>,Z,3B%")#D+C#+7'=
MX8%"A&'(@&O? $=4 VZ.#([X+)K[Y3:->+M!W0)7!/,^WBM/#[='C[URQ;$.WW)D9C%Y
MFD[MY^I_-JL_B-10[KQ#QB^M>/U/%=LJ?G1U$3K%]($P=')26.28EI"C-1>4
M+<$0C\@"MC2&=8_,\>VW3UHY_=FYZ+15!?CV0P:\>%XSWC4& &Y."J-2_)&4D98[$MGIY7?C.QV0%*.RN3,2/]X
M>F=>TP",7Z4HSTA8Y8.9=U0:?^1W IF73DV>EE-.X0?'+(&>Y1]R ")P5 47
M5-F37PCQ+.V[VL&$.ZJ",]67FV"!V!S#]]O8(CU+/V@!I."H.GX>#N>-QORY
MWV/^O,&8[Z@ZSD0E#WKH?7,\I62.X*=7*QIXR@-R J&QN7P)-,ES@^8MB6(9
MJ[K2'^Q0K*&>X8 ]@"!=H=A43A,!%X11AB@2XWMP_6 NR5P1(
MYO6_@$Q)"$]P=#9)>*)G%@* I60,!'(9*!!+\%Y1W+ $"F)G"D[Y@N9P$+DG
M"GTB8T0W'O7UL:I;ZGNN5YA#:826@=